Muscular channelopathy

Muscular channelopathies (Orphanet code 71864) are a group of rare inherited neuromuscular disorders caused by mutations in genes encoding ion channel proteins expressed in skeletal muscle. These ion channels — including sodium, chloride, calcium, and potassium channels — are essential for normal muscle excitability and contraction. When these channels malfunction, patients experience a range of symptoms related to abnormal muscle membrane excitability. This disease group encompasses several distinct conditions, including the non-dystrophic myotonias (such as myotonia congenita, paramyotonia congenita, and sodium channel myotonia), the periodic paralyses (hypokalemic periodic paralysis, hyperkalemic periodic paralysis), and other related disorders. Key symptoms across the group include myotonia (difficulty relaxing muscles after voluntary contraction), episodic muscle weakness or paralysis, and muscle stiffness. Symptoms may be triggered or worsened by factors such as cold exposure, exercise, rest after exercise, stress, or dietary changes (particularly potassium intake). Some patients may develop a fixed progressive myopathy over time. The primary body system affected is the skeletal muscular system, though cardiac involvement may occur in certain subtypes. Diagnosis is based on clinical features, electromyography (EMG) findings, genetic testing, and sometimes provocative testing. Treatment is largely symptomatic and varies by subtype. Mexiletine is commonly used for myotonia, while acetazolamide or dichlorphenamide may be prescribed for periodic paralysis. Lifestyle modifications, including avoidance of known triggers, are an important component of management. Genetic counseling is recommended for affected families.

Common questions about Muscular channelopathy